All In Biotech

Drug Trial Radar · NCT04228666

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 1, 2020

Primary completion

Feb 1, 2022

Study completion Feb 1, 2022

Sponsor

Lead sponsor
Hope Biosciences LLCIndustry
Sponsor type
Industry
Collaborators
Hope Biosciences Research Foundation
First posted
Jan 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Alzheimer's disease (AD). The study purpose is to evaluate the safety profile of four IV infusions of HB-adMSCs in subjects with clinical diagnosis of AD.

Conditions

  • Alzheimer Disease

Interventions

  • HB-adMSCsBiological

    Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GlucoseTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  2. CalciumTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  3. AlbuminTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  4. Total ProteinTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  5. SodiumTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  6. Total carbon dioxideTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  7. PotassiumTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  8. ChlorideTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  9. BUNTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  10. CreatinineTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  11. Alkaline phosphataseTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  12. Alanine aminotransferaseTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  13. Aspartate aminotransferaseTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  14. Total BilirubinTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  15. White blood cellTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  16. Red blood cellTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  17. HemoglobinTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  18. HematocritTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  19. Mean corpuscular volumeTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  20. Mean corpuscular hemoglobinTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  21. Mean corpuscular hemoglobin concentrationTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  22. Red cell distribution widthTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  23. NeutrophilsTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  24. LymphsTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  25. MonocytesTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  26. EosTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  27. BasophilsTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  28. Absolute neutrophilsTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  29. Absolute lymphsTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  30. Absolute monocytesTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  31. Absolute EosTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  32. Absolute BasosTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  33. Immature granulocytesTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  34. Absolute Immature granulocytesTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  35. PlateletsTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  36. Prothrombin timeTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.
  37. INRTime frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Network

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.